Terms: = Ovarian epithelial cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
238 results:
1. The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells.
Croft W; Pounds R; Jeevan D; Singh K; Balega J; Sundar S; Williams A; Ganesan R; Kehoe S; Ott S; Zuo J; Yap J; Moss P
Commun Biol; 2024 Sep; 7(1):1211. PubMed ID: 39341888
[TBL] [Abstract] [Full Text] [Related]
2. High-throughput drug screening identifies novel therapeutics for Low Grade Serous ovarian Carcinoma.
Pishas KI; Cowley KJ; Llaurado-Fernandez M; Kim H; Luu J; Vary R; Bowden NA; Campbell IG; Carey MS; Simpson KJ; Cheasley D
Sci Data; 2024 Sep; 11(1):1024. PubMed ID: 39300112
[TBL] [Abstract] [Full Text] [Related]
3. The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells.
Sue SH; Tseng WC; Wu ZS; Huang SM; Chen JL; Wu ZF; Lai HC
J Ovarian Res; 2024 Sep; 17(1):187. PubMed ID: 39272193
[TBL] [Abstract] [Full Text] [Related]
4. Pan-cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Miller CD; Lozada JR; Zorko NA; Elliott A; Makovec A; Radovich M; Heath EI; Agarwal N; Mckay RR; Garje R; Bastos BR; Hoon DSB; Orme JJ; Sartor O; VanderWalde A; Nabhan C; Sledge G; Shenderov E; Dehm SM; Lou E; Miller JS; Hwang JH; Antonarakis ES
Cancer Res Commun; 2024 May; 4(5):1369-1379. PubMed ID: 38709075
[TBL] [Abstract] [Full Text] [Related]
5. Static magnetic field reduces cisplatin resistance via increasing apoptosis pathways and genotoxicity in cancer cell lines.
Zafari J; Rastegar-Pouyani N; Javani Jouni F; Najjar N; Azarshin SZ; Jafarzadeh E; Abdolmaleki P; Hoseini Shirazi F
Sci Rep; 2024 Mar; 14(1):5792. PubMed ID: 38461218
[TBL] [Abstract] [Full Text] [Related]
6. STEAP3 Affects ovarian cancer Progression by Regulating Ferroptosis through the p53/SLC7A11 Pathway.
Han Y; Fu L; Kong Y; Jiang C; Huang L; Zhang H
Mediators Inflamm; 2024; 2024():4048527. PubMed ID: 38440354
[TBL] [Abstract] [Full Text] [Related]
7. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
8. BRCA1, BRCA2, and tp53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract] [Full Text] [Related]
9. Human Fallopian Tube-Derived Organoids with tp53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous ovarian cancer Phenotype In Vitro.
Dai Y; Xu J; Gong X; Wei J; Gao Y; Chai R; Lu C; Zhao B; Kang Y
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255960
[TBL] [Abstract] [Full Text] [Related]
10. FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models.
Galpin KJC; Rodriguez GM; Maranda V; Cook DP; Macdonald E; Murshed H; Zhao S; McCloskey CW; Chruscinski A; Levy GA; Ardolino M; Vanderhyden BC
Sci Rep; 2024 Jan; 14(1):787. PubMed ID: 38191799
[TBL] [Abstract] [Full Text] [Related]
11. p53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract] [Full Text] [Related]
12. Curcumin modulates cell type-specific miRNA networks to induce cytotoxicity in ovarian cancer cells.
Ravindran F; Mhatre A; Koroth J; Narayan S; Choudhary B
Life Sci; 2023 Dec; 334():122224. PubMed ID: 38084671
[TBL] [Abstract] [Full Text] [Related]
13. Identifying Explainable Machine Learning Models and a Novel SFRP2
Yang Z; Zhou D; Huang J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069266
[TBL] [Abstract] [Full Text] [Related]
14. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab treatment in Patients with Advanced ovarian cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract] [Full Text] [Related]
15. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
16. Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo.
Pereira M; Glogova A; Haagsma J; Stewart J; Shepherd TG; Petrik J
J Ovarian Res; 2023 Nov; 16(1):218. PubMed ID: 37986175
[TBL] [Abstract] [Full Text] [Related]
17. Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts.
Rutecki S; Pakuła-Iwańska M; Leśniewska-Bocianowska A; Matuszewska J; Rychlewski D; Uruski P; Stryczyński Ł; Naumowicz E; Szubert S; Tykarski A; Mikuła-Pietrasik J; Książek K
J Pathol; 2024 Feb; 262(2):198-211. PubMed ID: 37941520
[TBL] [Abstract] [Full Text] [Related]
18. Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.
Kramer C; Lanjouw L; Ruano D; Ter Elst A; Santandrea G; Solleveld-Westerink N; Werner N; van der Hout AH; de Kroon CD; van Wezel T; Berger L; Jalving M; Wesseling J; Smit V; de Bock GH; van Asperen CJ; Mourits M; Vreeswijk M; Bart J; Bosse T
J Pathol; 2024 Feb; 262(2):137-146. PubMed ID: 37850614
[TBL] [Abstract] [Full Text] [Related]
19. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study.
Shen W; Jing C; Tian W; Zhang W; Ren Y; Shan B; Wang H
Int J Gynecol Cancer; 2023 Nov; 33(11):1764-1770. PubMed ID: 37775281
[TBL] [Abstract] [Full Text] [Related]
20. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
[TBL] [Abstract] [Full Text] [Related]
[Next]
